description,result,original_n,original_es,original_es_type,original_es_95_CI,original_p_value,original_p_value_type,original_p_value_tails,replication_n,replication_es,replication_es_type,replication_es_95_CI,replication_p_value,replication_p_value_type,replication_p_value_tails,original_url,original_authors,original_title,original_journal,original_volume,original_issue,original_pages,original_year,replication_url
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #1: DU145 cell proliferation between siLuc and siPTEN,failure,6.0,15.55022,d,"[5.257552, 26.05874]",1.41e-07,t,,10,0.2433831,d,"[-1.009143, 1.481106]",0.7054361,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #2: DU145 cell proliferation between siLuc and siPTENP1,failure,6.0,6.153975,d,"[1.768501, 10.52976]",0.0001439379,t,,10,1.728561,d,"[0.1992304, 3.185692]",0.0147371,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #3: DU145 cell proliferation between siLuc and siPTEN+siPTENP1,failure,6.0,23.24239,d,"[7.984998, 37.9749]",5.95e-09,t,,10,1.832289,d,"[0.2738955, 3.317114]",0.01050397,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #4: DU145 cell proliferation between siPTEN+siPTENP1 and siPTEN,failure,6.0,7.692164,d,"[2.372797, 13.04715]",2.95e-05,t,,10,1.588906,d,"[0.09712672, 3.010802]",0.02309614,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #5: DU145 cell proliferation between siPTEN+siPTENP1 and siPTENP1,failure,6.0,17.08841,d,"[5.806536, 28.61677]",6.72e-08,t,,10,0.1037272,d,"[-1.140048, 1.341146]",0.8717794,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #6: PTEN mRNA expression between siLuc and siPTEN,success,6.0,3.550201,Glass' delta,"[0.01023859, 7.121244]",0.01991732,t,,10,2.113865,Glass' delta,"[0.1901405, 3.943944]",0.001698913,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #7: PTEN mRNA expression between siLuc and siPTENP1,success,6.0,2.485944,Glass' delta,"[-0.3100871, 5.194378]",0.03834298,t,,10,0.3524805,Glass' delta,"[-0.9296733, 1.593941]",0.5797451,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #8: PTEN mRNA expression between siLuc and siPTEN+siPTENP1,success,6.0,3.240964,Glass' delta,"[-0.07688066, 6.554284]",0.02393541,t,,10,2.056528,Glass' delta,"[0.1604913, 3.857627]",0.002616336,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #9: PTENP1 mRNA expression between siLuc and siPTEN,failure,6.0,3.514033,d,"[0.6315354, 6.298304]",0.01260772,t,,10,0.5172411,d,"[-0.7623987, 1.766394]",0.4371327,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #10: PTENP1 mRNA expression between siLuc and siPTENP1,success,6.0,5.702851,d,"[1.585428, 9.796224]",0.00221037,t,,10,2.245365,d,"[0.5624174, 3.851844]",0.007506881,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #11: PTENP1 mRNA expression between siLuc and siPTEN+siPTENP1,success,6.0,3.27789,d,"[0.5188403, 5.931193]",0.01593591,t,,10,1.616828,d,"[0.1176913, 3.045573]",0.03383443,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #12: PTEN protein expression between siLuc and siPTEN,inconclusive,,,Cliff's delta,,,,,10,1.0,Cliff's delta,"[0.8490597, 1.0]",0.007936508,z,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #13: PTEN protein expression between siLuc and siPTENP1,inconclusive,,,Cliff's delta,,,,,10,0.68,Cliff's delta,"[-0.1638394, 0.9491919]",0.0952381,z,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #14: PTEN protein expression between siLuc and siPTEN+siPTENP1,inconclusive,,,Cliff's delta,,,,,10,1.0,Cliff's delta,"[0.8490597, 1.0]",0.007936508,z,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #15: PTEN protein expression between siPTEN+siPTENP1 and siPTEN,inconclusive,,,Cliff's delta,,,,,10,0.52,Cliff's delta,"[-0.3223693, 0.9027654]",0.2222222,z,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #16: PTEN protein expression between siPTEN+siPTENP1 and siPTENP1,inconclusive,,,Cliff's delta,,,,,10,1.0,Cliff's delta,"[0.8490597, 1.0]",0.007936508,z,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #17: PTENP1 mRNA expression between pCMV and PTEN 3'UTR,failure,6.0,4.57509,d,"[1.110656, 7.977567]",0.004981447,t,,6,-0.3733547,d,"[-1.971197, 1.268137]",0.6712144,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #18: DU145 cell proliferation between pCMV and PTEN 3'UTR,success,6.0,16.21008,d,"[5.49337, 27.15589]",3.8e-05,t,,6,7.551127,d,"[2.318417, 12.81552]",0.000759987,t,,https://doi.org/10.1038/nature09144,Laura Poliseno; Leonardo Salmena; Jiangwen Zhang; Brett S. Carver; William J. Haveman; Pier Paolo Pandolfi,A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,Nature,465,7301.0,1033,2010,https://doi.org/10.7554/eLife.51019
This study tested whether glioblastoma stem cells can directly form blood vessels by differentiating into endothelial cells. Subexperiment #1: Tie2 expression in GSC83 vs HMVEC cells,failure,4.0,83.68295,d,"[13.27957, 155.2538]",6.61e-06,t,,5,2.516912,d,"[-0.1761535, 5.0607545]",0.03997007,t,,https://doi.org/10.1038/nature09557,Lucia Ricci‐Vitiani; Roberto Pallini; Mauro Biffoni; Matilde Todaro; Gloria Invernici; Tonia Cenci; Giulio Maira; Eugenio Parati; Giorgio Stassi; Luigi Maria Larocca; Ruggero De Maria,Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells,Nature,468,7325.0,824,2010,https://doi.org/10.7554/eLife.04363
This study tested whether glioblastoma stem cells can directly form blood vessels by differentiating into endothelial cells. Subexperiment #2: Tie2 expression in U87MG vs HMVEC cells,failure,4.0,84.78352,d,"[13.45515, 157.295]",6.36e-06,t,,6,2.501615,d,"[0.1266746, 4.750934]",0.02797935,t,,https://doi.org/10.1038/nature09557,Lucia Ricci‐Vitiani; Roberto Pallini; Mauro Biffoni; Matilde Todaro; Gloria Invernici; Tonia Cenci; Giulio Maira; Eugenio Parati; Giorgio Stassi; Luigi Maria Larocca; Ruggero De Maria,Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells,Nature,468,7325.0,824,2010,https://doi.org/10.7554/eLife.04363
This study tested whether glioblastoma stem cells can directly form blood vessels by differentiating into endothelial cells. Subexperiment #3: Tie2 expression in GSC83 vs U87MG cells,failure,4.0,1.100569,d,"[-1.193241, 3.20752]",0.4291293,t,,5,-0.01529775,d,"[-1.803326, 1.775138]",0.9872779,t,,https://doi.org/10.1038/nature09557,Lucia Ricci‐Vitiani; Roberto Pallini; Mauro Biffoni; Matilde Todaro; Gloria Invernici; Tonia Cenci; Giulio Maira; Eugenio Parati; Giorgio Stassi; Luigi Maria Larocca; Ruggero De Maria,Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells,Nature,468,7325.0,824,2010,https://doi.org/10.7554/eLife.04363
This study tested whether a specific GNAO1 mutation promotes breast cancer cell transformation. Subexperiment #1: Colony number of GNAO1-WT HMEC cells vs GNAO1-R243H HMEC cells,success,4.0,6.409596,d,"[0.5256721, 12.56598]",0.02348687,t,,6,4.317946,d,"[0.9980206, 7.567011]",0.006135204,t,,https://doi.org/10.1038/nature09208,Zhengyan Kan; Bijay S. Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M. Stern; Peng Yue; Peter M. Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P. Tomsho; Brock A. Peters; Kanan Pujara; Shaun Cordes; David P. Davis; Victoria Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S. Kaminker; David A. Eberhard; Paul Waring; Stephan C. Schuster; Zora Modrušan; Zemin Zhang; David Stokoe; Frédéric J. de Sauvage; Malek Faham; Somasekar Seshagiri,Diverse somatic mutation patterns and pathway alterations in human cancers,Nature,466,7308.0,869,2010,https://doi.org/10.7554/eLife.11566
"This study tested whether kinase-inactive BRAF mutations cooperate with RAS mutations to drive cancer through CRAF activation. Subexperiment #1: pERK levels in A375 cells treated with vehicle vs all three drug treatments (PD184352, sorafenib, and SB590885)",inconclusive,,,Cliff's delta,,,,,12,0.9259259,Cliff's delta,"[0.6262562, 0.9872088]",0.009090909,z,,https://doi.org/10.1016/j.cell.2009.12.040,Sonja J. Heidorn; Carla Milagre; Steven R. Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S. Reis‐Filho; Caroline J. Springer; Catrin Pritchard; Richard Marais,Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF,Cell,140,2.0,209,2010,https://doi.org/10.7554/eLife.11999
This study tested whether kinase-inactive BRAF mutations cooperate with RAS mutations to drive cancer through CRAF activation. Subexperiment #2: pERK levels in D04 cells treated with vehicle vs PD184352 and sorafenib,inconclusive,,,Cliff's delta,,,,,9,1.0,Cliff's delta,"[0.7476669, 1.0]",0.02380952,z,,https://doi.org/10.1016/j.cell.2009.12.040,Sonja J. Heidorn; Carla Milagre; Steven R. Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S. Reis‐Filho; Caroline J. Springer; Catrin Pritchard; Richard Marais,Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF,Cell,140,2.0,209,2010,https://doi.org/10.7554/eLife.11999
This study tested whether kinase-inactive BRAF mutations cooperate with RAS mutations to drive cancer through CRAF activation. Subexperiment #3: pERK levels in D04 cells treated with vehicle vs SB590885,inconclusive,,,Cliff's delta,,,,,6,0.1111111,Cliff's delta,"[-0.7078907, 0.8026747]",0.1,z,,https://doi.org/10.1016/j.cell.2009.12.040,Sonja J. Heidorn; Carla Milagre; Steven R. Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S. Reis‐Filho; Caroline J. Springer; Catrin Pritchard; Richard Marais,Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF,Cell,140,2.0,209,2010,https://doi.org/10.7554/eLife.11999
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #1: IC50 values of PLX4720 A375 cells vs PLX4720 HCT116 and MeWo cells",inconclusive,,,,,,,,12,,,,,,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #2: IC50 values of GDC-0879 A375 cells vs GDC-0879 HCT116 and MeWo cells",inconclusive,,,,,,,,12,,,,,,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #3: IC50 values of PD0325901 A375 cells vs PLX4720 and GDC-0879 A375 cells",inconclusive,,,,,,,,12,,,,,,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #4: IC50 values of PD0325901 HCT116 cells vs PLX4720 and GDC-0879 HCT116 cells",inconclusive,,,,,,,,12,,,,,,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #5: IC50 values of PD0325901 MeWo cells vs PLX4720 and GDC-0879 MeWo cells",inconclusive,,,,,,,,12,,,,,,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #6: pMEK/MEK levels between -shBRAF and +shBRAF cells treated with PLX4720",inconclusive,,,d,,,,,42,-0.02204385,d,"[-0.6267837, 0.5829707]",0.9432336,t,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #7: pMEK/MEK levels between -shCRAF and +shCRAF cells treated with PLX4720",inconclusive,,,d,,,,,42,1.128866,d,"[0.4696089, 1.775986]",0.0004538276,t,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #8: pMEK/MEK levels between -shBRAF and +shBRAF cells treated with GDC-0879",inconclusive,,,Cliff's delta,,,,,42,0.4058957,Cliff's delta,"[0.65311503, 0.08048876]",0.02424242,z,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
"This study tested whether RAF inhibitors paradoxically activate the MAPK signaling pathway in cells with wild-type BRAF, potentially promoting tumor growth. Subexperiment #9: pMEK/MEK levels between -shCRAF and +shCRAF cells treated with GDC-0879",inconclusive,,,Cliff's delta,,,,,42,0.1201814,Cliff's delta,"[-0.2107559, 0.4264033]",0.5046649,z,,https://doi.org/10.1038/nature08833,Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J. Brandhuber; Daniel J. Anderson; Ryan Alvarado; Mary J. C. Ludlam; David Stokoe; Susan L. Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P. Hoeflich; Bijay S. Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S. Friedman; Shiva Malek,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,Nature,464,7287.0,431,2010,https://doi.org/10.7554/eLife.09976
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #1: CD133 expression between TOP-GFPlow vs TOP-GFPhigh (450 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #2: CD133 expression between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #3: CD133 expression between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #4: CD24 expression between TOP-GFPlow vs TOP-GFPhigh (450 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #5: CD24 expression between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #6: CD24 expression between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #7: CD29 expression between TOP-GFPlow vs TOP-GFPhigh (450 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #8: CD29 expression between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #9: CD29 expression between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #10: CD44 expression between TOP-GFPlow vs TOP-GFPhigh (450 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #11: CD44 expression between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #12: CD44 expression between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #13: CD166 expression between TOP-GFPlow vs TOP-GFPhigh (450 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #14: CD166 expression between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #15: CD166 expression between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #16: Clonogenic frequency between TOP-GFPlow vs TOP-GFPhigh (450 culture),failure,18.0,0.9505299,w,"[0.9347403, 0.962573]",1.2899999999999999e-39,chi-squared,,18,0.4552718,w,"[0.335279, 0.5607297]",2.82e-10,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #17: Clonogenic frequency between TOP-GFPlow vs TOP-GFPhigh (CSC1 culture),failure,18.0,0.9505299,w,"[0.9347403, 0.962573]",1.2899999999999999e-39,chi-squared,,18,0.1584204,w,"[0.01719788, 0.29344561]",0.02815377,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #18: Clonogenic frequency between TOP-GFPlow vs TOP-GFPhigh (Co100 culture),failure,18.0,0.9505299,w,"[0.9347403, 0.962573]",1.2899999999999999e-39,chi-squared,,18,0.1988645,w,"[0.05891533, 0.33114741]",0.005859398,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #19: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + HGF (450 culture),failure,18.0,0.7710575,w,"[0.7066017, 0.8228232]",1.21e-26,chi-squared,,18,0.08796912,w,"[-0.0543158, 0.2267527]",0.2228685,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #20: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + HGF (CSC1 culture),failure,18.0,0.7710575,w,"[0.7066017, 0.8228232]",1.21e-26,chi-squared,,18,0.0418753,w,"[-0.1003279, 0.182402]",0.561752,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #21: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + HGF (Co100 culture),failure,18.0,0.7710575,w,"[0.7066017, 0.8228232]",1.21e-26,chi-squared,,18,0.256976,w,"[0.1197244, 0.3845891]",0.0003697778,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #22: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + MFCM (450 culture),failure,18.0,0.7281706,w,"[0.6539994, 0.7884753]",6.13e-24,chi-squared,,18,0.1010307,w,"[-0.0411666, 0.2392165]",0.1615367,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #23: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + MFCM (CSC1 culture),failure,18.0,0.7281706,w,"[0.6539994, 0.7884753]",6.13e-24,chi-squared,,18,0.1475765,w,"[0.006095581, 0.283265095]",0.04086671,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #24: Clonogenic frequency between TOP-GFPlow vs TOP-GFPlow + MFCM (Co100 culture),failure,18.0,0.7281706,w,"[0.6539994, 0.7884753]",6.13e-24,chi-squared,,18,0.3869178,w,"[0.2595293, 0.501072]",8.26e-08,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #25: Clonogenic frequency between TOP-GFPlow + HGF vs TOP-GFPlow + HGF + PHA (450 culture),failure,18.0,0.8932464,w,"[0.8604814, 0.9186533]",3.4700000000000003e-35,chi-squared,,18,0.04427603,w,"[-0.09794637, 0.18472612]",0.5395414,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #26: Clonogenic frequency between TOP-GFPlow + HGF vs TOP-GFPlow + HGF + PHA (CSC1 culture),failure,18.0,0.8932464,w,"[0.8604814, 0.9186533]",3.4700000000000003e-35,chi-squared,,18,0.4205246,w,"[0.2965775, 0.5305394]",5.64e-09,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #27: Clonogenic frequency between TOP-GFPlow + HGF vs TOP-GFPlow + HGF + PHA (Co100 culture),failure,18.0,0.8932464,w,"[0.8604814, 0.9186533]",3.4700000000000003e-35,chi-squared,,18,0.1634463,w,"[0.02235546, 0.29815375]",0.02352626,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #28: Clonogenic frequency between TOP-GFPlow + MFCM vs TOP-GFPlow + MFCM + PHA (450 culture),failure,18.0,0.9838607,w,"[0.9785927, 0.9878403]",2.56e-42,chi-squared,,18,0.5636529,w,"[0.4586533, 0.6531297]",5.71e-15,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #29: Clonogenic frequency between TOP-GFPlow + MFCM vs TOP-GFPlow + MFCM + PHA (CSC1 culture),failure,18.0,0.9838607,w,"[0.9785927, 0.9878403]",2.56e-42,chi-squared,,18,0.4762394,w,"[0.3588305, 0.5788129]",4.14e-11,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #30: Clonogenic frequency between TOP-GFPlow + MFCM vs TOP-GFPlow + MFCM + PHA (Co100 culture),failure,18.0,0.9838607,w,"[0.9785927, 0.9878403]",2.56e-42,chi-squared,,18,0.3030889,w,"[0.1687222, 0.4263963]",2.67e-05,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #31: Clonogenic frequency between TOP-GFPwhole vs TOP-GFPwhole + PHA (450 culture),reversal,18.0,0.03325293,w,"[-0.108868, 0.1740417]",0.6449664,chi-squared,,18,-0.5962971,w,"[-0.6804479, -0.496624]",1.43e-16,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #32: Clonogenic frequency between TOP-GFPwhole vs TOP-GFPwhole + PHA (CSC1 culture),failure,18.0,0.03325293,w,"[-0.108868, 0.1740417]",0.6449664,chi-squared,,18,0.6131651,w,"[0.516395, 0.6944728]",1.96e-17,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #33: Clonogenic frequency between TOP-GFPwhole vs TOP-GFPwhole + PHA (Co100 culture),reversal,18.0,0.03325293,w,"[-0.108868, 0.1740417]",0.6449664,chi-squared,,18,-0.3245137,w,"[-0.445643, -0.1917155]",6.91e-06,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #34: Tumorigenicity frequency between TOP-GFPlow vs TOP-GFPhigh (450 culture),failure,7.0,0.999,w,"[0.9981275, 0.9994661]",6.93e-16,chi-squared,,8,-0.0511812,w,"[-0.3928639, 0.3029188]",0.77218,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether Wnt signaling marks colon cancer stem cells and whether the tumor microenvironment can regulate this activity. Subexperiment #35: Tumorigenicity frequency between TOP-GFPlow vs TOP-GFPlow + MFCM (450 culture),failure,8.0,0.7359363,w,"[0.5712537, 0.8436579]",3.42e-07,chi-squared,,8,0.3219337,w,"[-0.03014416, 0.60294343]",0.06858681,chi-squared,,https://doi.org/10.1038/ncb2048,Louis Vermeulen; Felipe de Sousa e Melo; Maartje van der Heijden; Kate Cameron; Joan H. de Jong; Tijana Borovski; Jurriaan B. Tuynman; Matilde Todaro; Christian J. Merz; Hans M. Rodermond; Martin R. Sprick; Kristel Kemper; Dick J. Richel; Giorgio Stassi; Jan Paul Medema,Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,Nature Cell Biology,12,5.0,468,2010,https://doi.org/10.7554/eLife.45426
This study tested whether the kinase COT causes resistance to RAF inhibitors by reactivating the MAPK signaling pathway. Subexperiment #1: IC50 values of A375 cells vs HT29/OUMS-23 cells,inconclusive,,,d,,,,,6,4.816496,d,"[1.214733, 8.364609]",0.004131484,t,,https://doi.org/10.1038/nature09627,Cory M. Johannessen; Jesse S. Boehm; So Young Kim; Sapana Thomas; Leslie Wardwell; Laura A. Johnson; W. Marston Linehan; Nicolas Stransky; Alexandria P. Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R. Murray; Kourosh Salehi‐Ashtiani; David E. Hill; Marc Vidal; Jean J. Zhao; Xiaoping Yang; Ozan Alkan; Sung Joon Kim; Jennifer L. Harris; Christopher J. Wilson; Vic E. Myer; Peter M. Finan; David E. Root; Thomas M. Roberts; Todd R. Golub; Keith T. Flaherty; Reinhard Dummer; Barbara L. Weber; William R. Sellers; Robert Schlegel; Jennifer A. Wargo; William C. Hahn; Levi A. Garraway,COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,Nature,468,7326.0,968,2010,https://doi.org/10.7554/eLife.11414
This study tested whether the kinase COT causes resistance to RAF inhibitors by reactivating the MAPK signaling pathway. Subexperiment #2: IC50 values of A375 cells vs RPMI-7951 cells,inconclusive,,,,,,,,6,,,,,,,https://doi.org/10.1038/nature09627,Cory M. Johannessen; Jesse S. Boehm; So Young Kim; Sapana Thomas; Leslie Wardwell; Laura A. Johnson; W. Marston Linehan; Nicolas Stransky; Alexandria P. Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R. Murray; Kourosh Salehi‐Ashtiani; David E. Hill; Marc Vidal; Jean J. Zhao; Xiaoping Yang; Ozan Alkan; Sung Joon Kim; Jennifer L. Harris; Christopher J. Wilson; Vic E. Myer; Peter M. Finan; David E. Root; Thomas M. Roberts; Todd R. Golub; Keith T. Flaherty; Reinhard Dummer; Barbara L. Weber; William R. Sellers; Robert Schlegel; Jennifer A. Wargo; William C. Hahn; Levi A. Garraway,COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,Nature,468,7326.0,968,2010,https://doi.org/10.7554/eLife.11414
This study tested whether the kinase COT causes resistance to RAF inhibitors by reactivating the MAPK signaling pathway. Subexperiment #3: pMEK levels in RPMI-7951 cells treated with MAP3K8 inhibitor (20 uM) compared to DMSO (mu=1),inconclusive,,,d,,,,,8,-1.000118,d,"[-1.8405397, -0.1155457]",0.02545134,t,,https://doi.org/10.1038/nature09627,Cory M. Johannessen; Jesse S. Boehm; So Young Kim; Sapana Thomas; Leslie Wardwell; Laura A. Johnson; W. Marston Linehan; Nicolas Stransky; Alexandria P. Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R. Murray; Kourosh Salehi‐Ashtiani; David E. Hill; Marc Vidal; Jean J. Zhao; Xiaoping Yang; Ozan Alkan; Sung Joon Kim; Jennifer L. Harris; Christopher J. Wilson; Vic E. Myer; Peter M. Finan; David E. Root; Thomas M. Roberts; Todd R. Golub; Keith T. Flaherty; Reinhard Dummer; Barbara L. Weber; William R. Sellers; Robert Schlegel; Jennifer A. Wargo; William C. Hahn; Levi A. Garraway,COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,Nature,468,7326.0,968,2010,https://doi.org/10.7554/eLife.11414
This study tested whether the kinase COT causes resistance to RAF inhibitors by reactivating the MAPK signaling pathway. Subexperiment #4: pERK levels in RPMI-7951 cells treated with MAP3K8 inhibitor (20 uM) compared to DMSO (mu=1),inconclusive,,,d,,,,,8,-0.9381665,d,"[-1.76044756, -0.07249739]",0.03277309,t,,https://doi.org/10.1038/nature09627,Cory M. Johannessen; Jesse S. Boehm; So Young Kim; Sapana Thomas; Leslie Wardwell; Laura A. Johnson; W. Marston Linehan; Nicolas Stransky; Alexandria P. Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R. Murray; Kourosh Salehi‐Ashtiani; David E. Hill; Marc Vidal; Jean J. Zhao; Xiaoping Yang; Ozan Alkan; Sung Joon Kim; Jennifer L. Harris; Christopher J. Wilson; Vic E. Myer; Peter M. Finan; David E. Root; Thomas M. Roberts; Todd R. Golub; Keith T. Flaherty; Reinhard Dummer; Barbara L. Weber; William R. Sellers; Robert Schlegel; Jennifer A. Wargo; William C. Hahn; Levi A. Garraway,COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,Nature,468,7326.0,968,2010,https://doi.org/10.7554/eLife.11414
This study tested whether a tumor-penetrating peptide (iRGD) can enhance chemotherapy drug delivery and efficacy. Subexperiment #1: DOX accumulation in prostate tumor tissue of DOX+PBS vs DOX+iRGD,failure,6.0,7.409639,Glass' delta,"[0.8898267, 14.37962]",0.0154218,t,,8,-0.3177959,Glass' delta,"[-1.700543, 1.113274]",0.7365876,t,,https://doi.org/10.1126/science.1183057,Kazuki N. Sugahara; Tambet Teesalu; Priya Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel Greenwald; Erkki Ruoslahti,Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs,Science,328,5981.0,1031,2010,https://doi.org/10.7554/eLife.17584
This study tested whether a tumor-penetrating peptide (iRGD) can enhance chemotherapy drug delivery and efficacy. Subexperiment #2: Tumor weight of DOX+PBS vs DOX+iRGD,failure,20.0,1.610345,Glass' delta,"[0.4425053, 2.72709]",0.0005879201,t,,14,0.2240333,Glass' delta,"[-0.8398834, 1.270007]",0.825914,t,,https://doi.org/10.1126/science.1183057,Kazuki N. Sugahara; Tambet Teesalu; Priya Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel Greenwald; Erkki Ruoslahti,Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs,Science,328,5981.0,1031,2010,https://doi.org/10.7554/eLife.17584
"This study tested whether a tumor-penetrating peptide (iRGD) can enhance chemotherapy drug delivery and efficacy. Subexperiment #3: Percent body weight shift of PBS, DOX+PBS, DOX+iRGD",success,30.0,0.05997818343,r,"[-0.3069231241, 0.4113586476]",0.9525123,F,,21,0.3951733628,r,"[-0.04402342131, 0.7063611971]",0.2333175,F,,https://doi.org/10.1126/science.1183057,Kazuki N. Sugahara; Tambet Teesalu; Priya Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel Greenwald; Erkki Ruoslahti,Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs,Science,328,5981.0,1031,2010,https://doi.org/10.7554/eLife.17584
This study tested whether a tumor-penetrating peptide (iRGD) can enhance chemotherapy drug delivery and efficacy. Subexperiment #4: Prostate tumor apoptotic index of DOX+PBS vs DOX+iRGD,failure,20.0,2.298168,d,"[1.129156, 3.429967]",2.1e-05,t,,12,0.2512344,d,"[-0.8916921, 1.3818889]",0.669649,t,,https://doi.org/10.1126/science.1183057,Kazuki N. Sugahara; Tambet Teesalu; Priya Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel Greenwald; Erkki Ruoslahti,Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs,Science,328,5981.0,1031,2010,https://doi.org/10.7554/eLife.17584
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #1: Linear regression slopes of isocitrate-dependent NADPH production assay of wild-type IDH2 vs vector control,inconclusive,6.0,,Cliff's delta,,,,,14,1.0,Cliff's delta,"[0.9382054, 1.0]",0.0005827506,z,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #2: Linear regression slopes of isocitrate-dependent NADPH production assay of R172K mutant IDH2 vs vector control,inconclusive,6.0,,Cliff's delta,,,,,14,0.5102041,Cliff's delta,"[-0.2080929, 0.8709953]",0.1282051,z,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #3: Linear regression slopes of alpha-ketoglutarate-dependent NADPH consumption assay of wild-type IDH2 vs vector control,inconclusive,6.0,,Glass' delta,,,,,14,0.1273816,Glass' delta,"[-0.9277802, 1.172241]",0.7750359,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #4: Linear regression slopes of alpha-ketoglutarate-dependent NADPH consumption assay of R172K mutant IDH2 vs vector control,inconclusive,6.0,,Glass' delta,,,,,14,8.311091,Glass' delta,"[3.634329, 13.0013]",0.000576582,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #5: 2HG levels of R172K mutant IDH2 vs largest value observed in control/WT IDH2 cells,inconclusive,,,d,,,,,10,6.912087,d,"[3.71711, 10.10351]",4.14e-09,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #6: 2HG levels of R132C mutant IDH1 vs largest value observed in WT IDH,failure,5.0,8.404241,d,"[2.83925, 14.08517]",4.72e-05,t,,4,2.234498,d,"[0.2632168, 4.1670553]",0.02087446,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #7: 2HG levels of R172K mutant IDH2 vs largest value observed in WT IDH,success,9.0,6.745624,d,"[3.446096, 10.044942]",3.71e-08,t,,4,4.595493,d,"[1.053507, 8.224204]",0.002723826,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether mutant IDH enzymes produce an abnormal metabolite (2-HG) that drives leukemia development. Subexperiment #8: 2HG levels of R132C mutant IDH1 or R172K mutant IDH2 vs largest value observed in WT IDH,success,14.0,4.361155,d,"[2.617673, 6.089983]",4.86e-10,t,,8,3.086355,d,"[1.349622, 4.797836]",5.2e-05,t,,https://doi.org/10.7554/elife.12626,Oliver Fiehn; Megan R. Showalter; Christine E Schaner-Tooley,Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate,eLife,5,,,2016,https://doi.org/10.7554/eLife.26030
This study tested whether blocking BET bromodomain proteins could suppress the cancer-promoting gene c-Myc. Subexperiment #1: Relative MYC expression of MM.1S cells harvested 1 hr after (+)-JQ1 treatment vs cells 0 hr after (+)-JQ1 treatment,failure,2.0,2.482988,dz,"[-0.5946068, 5.7866542]",0.1766213,t,,5,17.40596,dz,"[6.015823, 28.411386]",2.6e-06,t,,https://doi.org/10.1016/j.cell.2011.08.017,Jake Delmore; Ghayas C. Issa; Madeleine E. Lemieux; Peter B. Rahl; Junwei Shi; Hannah M. Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M. Paranal; Jun Qi; Marta Chesi; Anna C. Schinzel; Michael R. McKeown; Timothy P. Heffernan; Christopher R. Vakoc; P. Leif Bergsagel; Irene M. Ghobrial; Paul G. Richardson; Richard A. Young; William C. Hahn; Kenneth C. Anderson; Andrew L. Kung; James E. Bradner; Constantine S. Mitsiades,BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc,Cell,146,6.0,904,2011,https://doi.org/10.7554/eLife.21253
This study tested whether blocking BET bromodomain proteins could suppress the cancer-promoting gene c-Myc. Subexperiment #2: Relative MYC expression of MM.1S cells harvested 8 hr after (+)-JQ1 treatment vs cells 0 hr after (+)-JQ1 treatment,failure,2.0,2.411988,dz,"[-0.605721, 5.633767]",0.1815468,t,,5,11.224173,dz,"[3.841858, 18.349709]",1.5e-05,t,,https://doi.org/10.1016/j.cell.2011.08.017,Jake Delmore; Ghayas C. Issa; Madeleine E. Lemieux; Peter B. Rahl; Junwei Shi; Hannah M. Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M. Paranal; Jun Qi; Marta Chesi; Anna C. Schinzel; Michael R. McKeown; Timothy P. Heffernan; Christopher R. Vakoc; P. Leif Bergsagel; Irene M. Ghobrial; Paul G. Richardson; Richard A. Young; William C. Hahn; Kenneth C. Anderson; Andrew L. Kung; James E. Bradner; Constantine S. Mitsiades,BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc,Cell,146,6.0,904,2011,https://doi.org/10.7554/eLife.21253
This study tested whether blocking BET bromodomain proteins could suppress the cancer-promoting gene c-Myc. Subexperiment #3: Overall survival of (+)-JQ1 vs vehicle control,failure,19.0,25.92992,HR,"[5.484926, 122.583391]",4e-05,chi-squared,,24,3.754594,HR,"[1.193745, 11.809033]",0.02364086,chi-squared,,https://doi.org/10.1016/j.cell.2011.08.017,Jake Delmore; Ghayas C. Issa; Madeleine E. Lemieux; Peter B. Rahl; Junwei Shi; Hannah M. Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M. Paranal; Jun Qi; Marta Chesi; Anna C. Schinzel; Michael R. McKeown; Timothy P. Heffernan; Christopher R. Vakoc; P. Leif Bergsagel; Irene M. Ghobrial; Paul G. Richardson; Richard A. Young; William C. Hahn; Kenneth C. Anderson; Andrew L. Kung; James E. Bradner; Constantine S. Mitsiades,BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc,Cell,146,6.0,904,2011,https://doi.org/10.7554/eLife.21253
This study tested whether blocking BET bromodomain proteins could suppress the cancer-promoting gene c-Myc. Subexperiment #4: Bioluminescence (tumor burden) of (+)-JQ1 vs vehicle control,failure,19.0,2.297534,d,"[1.09556, 3.460222]",0.0001094824,t,,18,0.557773,d,"[-0.417364, 1.516296]",0.2655945,t,,https://doi.org/10.1016/j.cell.2011.08.017,Jake Delmore; Ghayas C. Issa; Madeleine E. Lemieux; Peter B. Rahl; Junwei Shi; Hannah M. Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M. Paranal; Jun Qi; Marta Chesi; Anna C. Schinzel; Michael R. McKeown; Timothy P. Heffernan; Christopher R. Vakoc; P. Leif Bergsagel; Irene M. Ghobrial; Paul G. Richardson; Richard A. Young; William C. Hahn; Kenneth C. Anderson; Andrew L. Kung; James E. Bradner; Constantine S. Mitsiades,BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc,Cell,146,6.0,904,2011,https://doi.org/10.7554/eLife.21253
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #1: Primary tumor growth between LM-4175 with or without Cav1 WT or Cav1 KO pMEFs,success,34.0,0.1680213,r,"[-0.1803942, 0.4789723]",0.6415434,chi-squared,,61,0.02751682,r,"[-0.225869, 0.2774153]",0.9782731,chi-squared,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #2: Total metastatic foci per mouse of LM-4175 vs LM-4175 + Cav1 WT,failure,18.0,0.8888889,Cliff's delta,"[0.469068, 0.9810331]",0.001023486,z,,36,0.2076923,Cliff's delta,"[-0.07528094, 0.45970759]",0.327788,z,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #3: Total metastatic foci per mouse of LM-4175 vs LM-4175 + Cav1 KO,success,21.0,0.4222222,Cliff's delta,"[-0.0821183, 0.7544005]",0.1460453,z,,35,0.404,Cliff's delta,"[0.09630774, 0.64121404]",0.0623144,z,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #4: Total metastatic foci per mouse of LM-4175 + Cav1 WT vs LM-4175 + Cav1 KO,failure,27.0,0.4777778,Cliff's delta,"[0.03119762, 0.76534551]",0.03519667,z,,51,-0.1984615,Cliff's delta,"[-0.4731837, 0.1114388]",0.2227251,z,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #5: Percent of fibronectin fibers within +/- 20 degrees from LM-4175 vs LM-4175 + Cav1 WT,failure,13.0,1.0,Cliff's delta,"[0.9176244, 1.0]",0.001554002,z,,13,0.05,Cliff's delta,"[-0.6029312, 0.6628181]",0.9432789,z,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #6: Percent of fibronectin fibers within +/- 20 degrees from LM-4175 + Cav1 WT vs LM-4175 + Cav1 KO,success,18.0,0.7,Cliff's delta,"[0.2140474, 0.908207]",0.01165501,z,,15,0.5357143,Cliff's delta,"[-0.0736732, 0.8538133]",0.09386169,z,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
This study tested whether loss of caveolin-1 in stromal cells promotes tumor invasion by stiffening the tumor microenvironment. Subexperiment #7: Correlation of percent of fibronectin fibers within +/- 20 degrees and number of metastasis,reversal,25.0,0.6766662,Spearman's r,"[0.3842812, 0.8456849]",0.0002038955,rho,,20,-0.5003121,Spearman's r,"[-0.77192894, -0.07422445]",0.02466544,rho,,https://doi.org/10.1016/j.cell.2011.05.040,Jacky G. Goetz; Susana Minguet; Inmaculada Navarro‐Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J. Klein‐Szanto; Ricardo Garcı́a; Patricia J. Keely; Paloma Sánchez‐Mateos; Edna Cukierman; Miguel Á. del Pozo,Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis,Cell,146,1.0,148,2011,https://doi.org/10.7554/eLife.45120
"This study tested whether computational analysis of gene expression data can identify new uses for existing drugs, specifically cimetidine for lung cancer. Subexperiment #1: Relative tumor volume of A549 xenografts treated with cimetidine vs vehicle",success,12.0,1.355951,d,"[0.05518853, 2.60415546]",0.04073944,t,,27,0.928691,d,"[0.1232132, 1.7175443]",0.02357807,t,,https://doi.org/10.1126/scitranslmed.3001318,Marina Sirota; Joel T. Dudley; Jeewon Kim; Annie Chiang; Alex A. Morgan; E. Alejandro Sweet‐Cordero; Julien Sage; Atul J. Butte,Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data,Science Translational Medicine,3,96.0,96ra77,2011,https://doi.org/10.7554/eLife.17044
"This study tested whether computational analysis of gene expression data can identify new uses for existing drugs, specifically cimetidine for lung cancer. Subexperiment #2: Relative tumor volume of A549 xenografts treated with DOX vs vehicle",success,12.0,3.004983,d,"[1.251697, 4.695657]",0.0003985327,t,,18,1.263148,d,"[0.05315685, 2.43910131]",0.04057874,t,,https://doi.org/10.1126/scitranslmed.3001318,Marina Sirota; Joel T. Dudley; Jeewon Kim; Annie Chiang; Alex A. Morgan; E. Alejandro Sweet‐Cordero; Julien Sage; Atul J. Butte,Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data,Science Translational Medicine,3,96.0,96ra77,2011,https://doi.org/10.7554/eLife.17044
"This study tested whether computational analysis of gene expression data can identify new uses for existing drugs, specifically cimetidine for lung cancer. Subexperiment #3: Relative tumor volume of ACHN xenografts treated with cimetidine vs vehicle",failure,12.0,0.6081211,d,"[-0.5678437, 1.7556535]",0.31699,t,,30,-0.181138,d,"[-0.8967692, 0.5376991]",0.4863648,z,,https://doi.org/10.1126/scitranslmed.3001318,Marina Sirota; Joel T. Dudley; Jeewon Kim; Annie Chiang; Alex A. Morgan; E. Alejandro Sweet‐Cordero; Julien Sage; Atul J. Butte,Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data,Science Translational Medicine,3,96.0,96ra77,2011,https://doi.org/10.7554/eLife.17044
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #1: PTEN-3'UTR luciferase reporter activity of siNC vs siSERINC1,failure,8.0,3.616474,d,"[1.147255, 6.003115]",0.002190081,t,,8,-0.1249458,d,"[-1.507507, 1.267743]",0.8655577,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #2: PTEN-3'UTR luciferase reporter activity of siNC vs siZNF460,success,8.0,0.9328917,d,"[-0.5789872, 2.378636]",0.2351748,t,,8,0.6358212,d,"[-0.8181923, 2.041438]",0.4031949,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #3: PTEN-3'UTR luciferase reporter activity of siNC vs siVAPA,failure,8.0,5.653017,Glass' delta,"[1.227296, 10.16045]",0.0007419815,t,,8,0.1556105,Glass' delta,"[-1.2475, 1.534436]",0.8291362,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #4: PTEN-3'UTR luciferase reporter activity of siNC vs siCNOT6L,failure,8.0,3.252155,Glass' delta,"[0.407338, 6.0475]",0.004015118,t,,8,0.3363867,Glass' delta,"[-1.098502, 1.720333]",0.6850368,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #5: PTEN-3'UTR luciferase reporter activity of siNC vs siPTEN,success,8.0,8.586207,Glass' delta,"[2.109776, 15.2773]",0.0003724277,t,,8,2.484508,Glass' delta,"[0.1009866, 4.77607]",0.02857143,z,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #6: PTEN-3'UTR luciferase reporter activity of EV vs SERINC1-3'UTR,reversal,8.0,2.704109,d,"[0.6200775, 4.693687]",0.008718023,t,,12,-1.917353,d,"[-3.289486, -0.484107]",0.007735024,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #7: PTEN-3'UTR luciferase reporter activity of EV vs VAPA-3'UTR1,failure,8.0,4.625142,Glass' delta,"[0.8937053, 8.384744]",0.01214254,t,,12,-1.441733,Glass' delta,"[-2.826101, 0.02658932]",0.0106408,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #8: PTEN-3'UTR luciferase reporter activity of EV vs VAPA-3'UTR2,reversal,8.0,5.519549,d,"[2.156096, 8.832212]",0.0002331278,t,,12,-2.789833,d,"[-4.411396, -1.104969]",0.0006895721,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #9: PTEN-3'UTR luciferase reporter activity of EV vs CNOT6L-3'UTR1,reversal,8.0,4.569352,d,"[1.66362, 7.408486]",0.0006512861,t,,12,-2.551886,d,"[-4.100061, -0.9400836]",0.00129412,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #10: PTEN-3'UTR luciferase reporter activity of EV vs CNOT6L-3'UTR2,reversal,8.0,5.195923,Glass' delta,"[1.081294, 9.369]",0.0005563789,t,,12,-2.293205,Glass' delta,"[-4.037522, -0.4709422]",0.001362887,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #11: PTEN-3'UTR luciferase reporter activity of EV vs PTEN-3'UTR,reversal,8.0,6.038505,Glass' delta,"[1.348041, 10.82966]",0.0007993519,t,,10,-3.154098,Glass' delta,"[-5.328959, -0.9197438]",0.0003991548,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #12: PTEN expression of siNC vs siSERINC1 in wild-type HCT116 cells,failure,8.0,5.508277,d,"[2.150352, 8.815231]",0.0002357769,t,,6,1.48191,d,"[-0.4619813, 3.302322]",0.143716,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #13: PTEN expression of siNC vs siVAPA in wild-type HCT116 cells,success,8.0,6.479283,d,"[2.638413, 10.2841]",9.51e-05,t,,6,4.413548,d,"[1.040123, 7.719426]",0.005671521,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #14: PTEN expression of siNC vs siCNOT6L in wild-type HCT116 cells,failure,8.0,6.186268,d,"[2.492441, 9.839689]",0.0001234589,t,,6,2.085728,d,"[-0.1010185, 4.142058]",0.06300514,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #15: PTEN expression of siNC vs siPTEN in wild-type HCT116 cells,success,8.0,11.81928,Glass' delta,"[3.029334, 20.95182]",0.0001647319,t,,6,5.788292,Glass' delta,"[0.5530485, 11.30629]",0.0005585633,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #16: PTEN expression of siNC vs siSERINC1 in Dicer-Ex5 HCT116 cells,success,8.0,2.975367,d,"[0.7811132, 5.077952]",0.005636838,t,,8,2.802613,d,"[0.6790372, 4.832643]",0.007422007,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #17: PTEN expression of siNC vs siVAPA in Dicer-Ex5 HCT116 cells,success,8.0,1.004925,d,"[-0.5231449, 2.463199]",0.2050917,t,,8,0.6332674,d,"[-0.8203145, 2.038622]",0.404974,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #18: PTEN expression of siNC vs siCNOT6L in Dicer-Ex5 HCT116 cells,success,8.0,2.708333,Glass' delta,"[0.193857, 5.142675]",0.007176665,t,,8,3.323902,Glass' delta,"[0.4344105, 6.168055]",0.03894628,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #19: PTEN expression of siNC vs siPTEN in Dicer-Ex5 HCT116 cells,failure,8.0,20.5625,Glass' delta,"[5.434002, 35.36035]",3.16e-05,t,,8,2.075854,Glass' delta,"[-0.07814925, 4.119009]",0.006015906,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #20: cell proliferation of siNC vs siVAPA in wild-type HCT116 cells,success,6.0,6.088486,d,"[1.742122, 10.42311]",0.001728131,t,,8,2.171778,d,"[0.2904801, 3.956579]",0.02190393,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #21: cell proliferation of siNC vs siCNOT6L in wild-type HCT116 cells,failure,6.0,8.120974,d,"[2.537121, 13.75216]",0.0005738803,t,,8,0.4258394,d,"[-0.996725, 1.814815]",0.5690665,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #22: cell proliferation of siNC vs siPTEN in wild-type HCT116 cells,failure,6.0,8.193411,d,"[2.564739, 13.87136]",0.0005544865,t,,8,2.363073,d,"[0.4112248, 4.218505]",0.01557516,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #23: cell proliferation of siPTEN vs siVAPA in Dicer-Ex5 HCT116 cells,success,6.0,4.836069,d,"[1.223106, 8.396053]",0.004070677,t,,8,1.491057,d,"[-0.1653935, 3.059672]",0.07951859,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #24: cell proliferation of siPTEN vs siCNOT6L in Dicer-Ex5 HCT116 cells,success,6.0,2.919355,Glass' delta,"[-0.1722412, 5.970023]",0.0220685,t,,8,2.839691,Glass' delta,"[0.2468907, 5.359584]",0.01399455,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #25: cell proliferation of siNC vs siPTEN in Dicer-Ex5 HCT116 cells,success,6.0,7.677419,Glass' delta,"[0.9427065, 14.88883]",0.005551034,t,,8,2.677871,Glass' delta,"[0.1814093, 5.092549]",0.002836135,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #26: cell proliferation of siNC vs siVAPA in DU145 cells,success,6.0,3.680851,Glass' delta,"[0.04586493, 7.362028]",0.01632962,t,,10,0.4207117,Glass' delta,"[-0.8743082, 1.667941]",0.6034163,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #27: cell proliferation of siNC vs siCNOT6L in DU145 cells,failure,6.0,3.147803,d,"[0.4555848, 5.730333]",0.01822076,t,,10,-0.6520032,d,"[-1.912009, 0.6455526]",0.3327408,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether a pseudogene (PTENP1) can regulate the tumor suppressor PTEN by competing for microRNA binding. Subexperiment #28: cell proliferation of siNC vs siPTEN in DU145 cells,success,6.0,5.480214,d,"[1.493808, 9.435297]",0.002565041,t,,10,1.624701,d,"[0.123476, 3.055395]",0.03318543,t,,https://doi.org/10.1016/j.cell.2011.09.029,Yvonne Tay; Lev M. Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian A. Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi,Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs,Cell,147,2.0,344,2011,https://doi.org/10.7554/eLife.56651
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #1: let-7b expression in CD44+ cells relative to CD44- cells,inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #2: miR-34a expression in CD44+ cells relative to CD44- cells,inconclusive,,,,,,,,1,,,,,,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #3: Tumor weights of LAPC4 cells expressing miR-34a vs negative control,failure,12.0,1.21875,Glass' delta,"[-0.1704775, 2.5274522]",0.0294672,t,,14,-0.1689181,Glass' delta,"[-1.2139127, 0.8896899]",0.7121999,t,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #4: miR-34a expression in tumors expression miR-34a vs negative control.,inconclusive,,,,,,,,14,,,,,,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #5: CD44 expression in tumors,inconclusive,,,d,,,,,14,-0.221784,d,"[-1.268563, 0.8340664]",0.6855224,t,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #6: Luciferase values of miR-34a expression with wild-type reporter vs M1M2 reporter,success,6.0,0.8459824,d,"[-0.8959904, 2.4987841]",0.3586755,t,,32,0.2600372,d,"[-0.4381443, 0.9539404]",0.3808965,z,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #7: Luciferase values of miR-34a expression with wild-type reporter vs control expression with wild-type reporter,success,3.0,2.18464,d,"[-0.0856468, 4.4395266]",0.06328464,t,,16,0.02047842,d,"[-0.4699046, 0.5101851]",0.6321716,z,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether the microRNA miR-34a suppresses prostate cancer stem cells and metastasis by targeting the CD44 protein. Subexperiment #8: Luciferase values of miR-34a expression with M1M2 reporter vs control expression with M1M2 reporter,failure,3.0,2.114064,d,"[-0.1067127, 4.311473]",0.06715723,t,,16,-0.3576466,d,"[-0.8582565, 0.1540444]",0.7819519,z,,https://doi.org/10.1038/nm.2284,Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun‐Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F. Wiggins; Andreas G. Bader; Randy Fagin; David T. Brown; Dean G. Tang,The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,Nature Medicine,17,2.0,211,2011,https://doi.org/10.7554/eLife.43511
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #1: IC50 values of MV4;11 cells vs largest dose (100 µM) tested in K-562 cells,inconclusive,,,d,,,,,5,9.226546,d,"[3.132934, 15.452539]",3.26e-05,t,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #2: Relative BCL2 expression of MV4;11 cells treated with I-BET151 vs constant of 1 (DMSO treated cells),success,3.0,26.0,d,"[4.098563, 48.254647]",0.0004927322,t,,3,10.30995,d,"[1.540743, 19.855333]",0.003121253,t,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #3: Relative BCL2 expression of K-562 cells treated with I-BET151 vs constant of 1 (DMSO treated cells),failure,3.0,1.3,d,"[-0.3837554, 2.8812568]",0.1531738,t,,3,-2.035979,d,"[-4.1703266, 0.1304595]",0.07185459,t,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #4: Relative BCL2 expression of MV4;11 cells treated with I-BET151 vs K-562 cells treated with I-BET151,success,6.0,17.3413,d,"[5.896563, 29.037485]",2.91e-05,t,,6,14.06732,d,"[4.725533, 23.594545]",6.66e-05,t,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #5: Survival of I-BET151 vs vehicle control,failure,10.0,10.32306,HR,"[1.508854, 70.626861]",0.01734749,chi-squared,,23,1.439196,HR,"[0.4544079, 4.558209]",0.535919,chi-squared,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether blocking BET proteins from binding chromatin could treat MLL-fusion leukemia by disrupting cancer-promoting gene expression. Subexperiment #6: Leukaemia burden in bone marrow of I-BET151 vs vehicle control,inconclusive,,,Cliff's delta,,,,,18,0.1,Cliff's delta,"[-0.4160938, 0.5673656]",0.7618264,z,,https://doi.org/10.1038/nature10509,Mark A. Dawson; Rab K. Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C. Robson; Chun‐wa Chung; Carsten Hopf; Mikhail M. Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Sören Beinke; Trevor Chapman; Emma J. Roberts; Peter E. Soden; Kurt R. Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K. Burnett; Philip D. Jeffrey; Gerard Drewes; Kevin Lee; Brian J.P. Huntly; Tony Kouzarides,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,Nature,478,7370.0,529,2011,https://doi.org/10.7554/eLife.25306
This study tested whether genetic markers can predict which cancer cells will respond to specific drugs. Subexperiment #1: Effective concentrations of Ewing's sarcoma cell lines vs osteosarcoma cell lines,failure,13.0,0.925,Cliff's delta,"[0.6221087, 0.9870526]",0.0050129,z,,12,0.3142857,Cliff's delta,"[-0.4619786, 0.8178903]",0.3441826,z,,https://doi.org/10.1038/nature11005,Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy Milano; Graham R. Bignell; Ah Ting Tam; Helen Davies; Jesse A. Stevenson; Syd Barthorpe; Stephen Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O’Brien; Jessica L. Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam P. Butler; Hwan Geun Choi; Jae Won Chang; José Baselga; Ivan Stamenkovic; Jeffrey A. Engelman; Sreenath V. Sharma; Olivier Delattre; Julio Sáez-Rodríguez; Nathanael S. Gray; Jeffrey Settleman; P. Andrew Futreal; Daniel A. Haber; Michael R. Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H. Benes,Systematic identification of genomic markers of drug sensitivity in cancer cells,Nature,483,7391.0,570,2012,https://doi.org/10.7554/eLife.29747
This study tested whether genetic markers can predict which cancer cells will respond to specific drugs. Subexperiment #2: Effective concentrations of Ewing's sarcoma cell lines vs osteosarcoma cell lines,failure,13.0,0.925,Cliff's delta,"[0.6221087, 0.9870526]",0.0050129,z,,12,0.3714286,Cliff's delta,"[-0.3877911, 0.830379]",0.2636006,z,,https://doi.org/10.1038/nature11005,Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy Milano; Graham R. Bignell; Ah Ting Tam; Helen Davies; Jesse A. Stevenson; Syd Barthorpe; Stephen Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O’Brien; Jessica L. Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam P. Butler; Hwan Geun Choi; Jae Won Chang; José Baselga; Ivan Stamenkovic; Jeffrey A. Engelman; Sreenath V. Sharma; Olivier Delattre; Julio Sáez-Rodríguez; Nathanael S. Gray; Jeffrey Settleman; P. Andrew Futreal; Daniel A. Haber; Michael R. Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H. Benes,Systematic identification of genomic markers of drug sensitivity in cancer cells,Nature,483,7391.0,570,2012,https://doi.org/10.7554/eLife.29747
This study tested whether genetic markers can predict which cancer cells will respond to specific drugs. Subexperiment #3: IC50 values of EWS-FLI1 transformed cells vs FUS-CHOP transformed cells,inconclusive,6.0,3.390155,Glass' delta,"[-0.03433533, 6.827256]",0.02174274,t,,6,,Glass' delta,,,,,https://doi.org/10.1038/nature11005,Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy Milano; Graham R. Bignell; Ah Ting Tam; Helen Davies; Jesse A. Stevenson; Syd Barthorpe; Stephen Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O’Brien; Jessica L. Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam P. Butler; Hwan Geun Choi; Jae Won Chang; José Baselga; Ivan Stamenkovic; Jeffrey A. Engelman; Sreenath V. Sharma; Olivier Delattre; Julio Sáez-Rodríguez; Nathanael S. Gray; Jeffrey Settleman; P. Andrew Futreal; Daniel A. Haber; Michael R. Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H. Benes,Systematic identification of genomic markers of drug sensitivity in cancer cells,Nature,483,7391.0,570,2012,https://doi.org/10.7554/eLife.29747
This study tested whether genetic markers can predict which cancer cells will respond to specific drugs. Subexperiment #4: IC50 values of SK-N-MC cells vs EWS-FLI1 transformed cells,inconclusive,6.0,0.8026133,Glass' delta,"[-1.028116, 2.48923]",0.2988429,t,,6,,Glass' delta,,,,,https://doi.org/10.1038/nature11005,Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy Milano; Graham R. Bignell; Ah Ting Tam; Helen Davies; Jesse A. Stevenson; Syd Barthorpe; Stephen Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O’Brien; Jessica L. Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam P. Butler; Hwan Geun Choi; Jae Won Chang; José Baselga; Ivan Stamenkovic; Jeffrey A. Engelman; Sreenath V. Sharma; Olivier Delattre; Julio Sáez-Rodríguez; Nathanael S. Gray; Jeffrey Settleman; P. Andrew Futreal; Daniel A. Haber; Michael R. Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H. Benes,Systematic identification of genomic markers of drug sensitivity in cancer cells,Nature,483,7391.0,570,2012,https://doi.org/10.7554/eLife.29747
This study tested whether genetic markers can predict which cancer cells will respond to specific drugs. Subexperiment #5: IC50 values of control siRNA transfected cells vs EWS-FLI1 siRNA transfected cells,inconclusive,6.0,12.45259,d,"[4.142031, 20.9142]",0.0001077913,t,,6,,d,,,,,https://doi.org/10.1038/nature11005,Mathew J. Garnett; Elena J. Edelman; Sonja J. Heidorn; Chris Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I. Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy Milano; Graham R. Bignell; Ah Ting Tam; Helen Davies; Jesse A. Stevenson; Syd Barthorpe; Stephen Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O’Brien; Jessica L. Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam P. Butler; Hwan Geun Choi; Jae Won Chang; José Baselga; Ivan Stamenkovic; Jeffrey A. Engelman; Sreenath V. Sharma; Olivier Delattre; Julio Sáez-Rodríguez; Nathanael S. Gray; Jeffrey Settleman; P. Andrew Futreal; Daniel A. Haber; Michael R. Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H. Benes,Systematic identification of genomic markers of drug sensitivity in cancer cells,Nature,483,7391.0,570,2012,https://doi.org/10.7554/eLife.29747
This study tested whether blocking the CD47-SIRPa 'don't eat me' signal can enable immune cells to attack cancer cells. Subexperiment #1: Tumor weights of IgG vs anti-CD47 (MIAP410),failure,10.0,2.541195,Glass' delta,"[0.402931, 4.597614]",0.00469753,t,,13,-1.131789,Glass' delta,"[-2.355, 0.1594191]",0.103811,t,,https://doi.org/10.1073/pnas.1121623109,Stephen B. Willingham; Jens-Peter Volkmer; Andrew J. Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S. Mitra; Jian Wang; Humberto Contreras-Trujillo; R.K. Martin; Justin D. Cohen; Patricia Lovelace; Ferenc A. Scheeren; Mark P. Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha Jairaj Naik; Theresa A. Storm; Adriane Mosley; Badreddin Edris; Seraina Schmid; Chris K. Sun; Mei‐Sze Chua; Oihana Murillo; Pradeep S. Rajendran; C. Adriel; Robert Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K. Steinberg; Gordon Li; Samuel So; Ravindra Majeti; Griffith R. Harsh; Matt van de Rijn; Nelson N.H. Teng; John B. Sunwoo; Ash A. Alizadeh; Michael F. Clarke; Irving L. Weissman,The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors,Proceedings of the National Academy of Sciences of the United States of America,109,17.0,6662,2012,https://doi.org/10.7554/eLife.18173
"This study tested whether blocking the CD47-SIRPa 'don't eat me' signal can enable immune cells to attack cancer cells. Subexperiment #2: hematological counts of NT, IgG, CD47",inconclusive,6.0,,,,,,,20,,,,,,,https://doi.org/10.1073/pnas.1121623109,Stephen B. Willingham; Jens-Peter Volkmer; Andrew J. Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S. Mitra; Jian Wang; Humberto Contreras-Trujillo; R.K. Martin; Justin D. Cohen; Patricia Lovelace; Ferenc A. Scheeren; Mark P. Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha Jairaj Naik; Theresa A. Storm; Adriane Mosley; Badreddin Edris; Seraina Schmid; Chris K. Sun; Mei‐Sze Chua; Oihana Murillo; Pradeep S. Rajendran; C. Adriel; Robert Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K. Steinberg; Gordon Li; Samuel So; Ravindra Majeti; Griffith R. Harsh; Matt van de Rijn; Nelson N.H. Teng; John B. Sunwoo; Ash A. Alizadeh; Michael F. Clarke; Irving L. Weissman,The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors,Proceedings of the National Academy of Sciences of the United States of America,109,17.0,6662,2012,https://doi.org/10.7554/eLife.18173
This study tested whether gut bacteria contribute to colorectal cancer development during intestinal inflammation. Subexperiment #1: Intrinsic doubling time of bacterial growth of pks island deletion vs wild-type,inconclusive,,,d,,,,,6,1.188402,d,"[-0.6541789, 2.9193827]",0.2192356,t,,https://doi.org/10.1126/science.1224820,Janelle C. Arthur; Ernesto Peréz-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M. Uronis; Ting-Jia Fan; Barry J. Campbell; Turki S. Abujamel; Belgin Dogan; Arlin B. Rogers; Jonathan M. Rhodes; Alain Stintzi; Kenneth W. Simpson; Jonathan J. Hansen; Temitope O. Keku; Anthony A. Fodor; Christian Jobin,Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota,Science,338,6103.0,120,2012,https://doi.org/10.7554/eLife.34364
This study tested whether gut bacteria contribute to colorectal cancer development during intestinal inflammation. Subexperiment #2: Overall survival of germ-free Il10-/- mice mono-associated with E.coli NC101 or NC101deltapks,success,20.0,1.691181,HR,"[0.3147196, 9.087749]",0.5402393,chi-squared,,84,1.945032,HR,"[1.095877, 3.452168]",0.0230397,chi-squared,,https://doi.org/10.1126/science.1224820,Janelle C. Arthur; Ernesto Peréz-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M. Uronis; Ting-Jia Fan; Barry J. Campbell; Turki S. Abujamel; Belgin Dogan; Arlin B. Rogers; Jonathan M. Rhodes; Alain Stintzi; Kenneth W. Simpson; Jonathan J. Hansen; Temitope O. Keku; Anthony A. Fodor; Christian Jobin,Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota,Science,338,6103.0,120,2012,https://doi.org/10.7554/eLife.34364
This study tested whether melanoma cells release exosomes that reprogram bone marrow cells to prepare distant sites for metastasis. Subexperiment #1: Met expression in shMet exosomes compared to a constant of 1 (shScr exosomes),inconclusive,,,,,,,,3,,,,,,,https://doi.org/10.1038/nm.2753,Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa‐Silva; Gema Moreno‐Bueno; Marta Hergueta‐Redondo; Caitlin Williams; Guillermo García‐Santos; Cyrus M. Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A. Garcia; Margaret K. Callahan; Jianda Yuan; Vilma R. Martins; Johan Skog; Rosandra N. Kaplan; Mary S. Brady; Jedd D. Wolchok; Paul B. Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden,Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET,Nature Medicine,18,6.0,883,2012,https://doi.org/10.7554/eLife.39944
This study tested whether melanoma cells release exosomes that reprogram bone marrow cells to prepare distant sites for metastasis. Subexperiment #2: Metastatic burden in lungs of shScr injected mice vs liposome,failure,14.0,2.292559,d,"[0.8800974, 3.6511361]",0.001052166,t,,12,0.2736501,d,"[-0.8707803, 1.4047364]",0.6456962,t,,https://doi.org/10.1038/nm.2753,Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa‐Silva; Gema Moreno‐Bueno; Marta Hergueta‐Redondo; Caitlin Williams; Guillermo García‐Santos; Cyrus M. Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A. Garcia; Margaret K. Callahan; Jianda Yuan; Vilma R. Martins; Johan Skog; Rosandra N. Kaplan; Mary S. Brady; Jedd D. Wolchok; Paul B. Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden,Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET,Nature Medicine,18,6.0,883,2012,https://doi.org/10.7554/eLife.39944
This study tested whether melanoma cells release exosomes that reprogram bone marrow cells to prepare distant sites for metastasis. Subexperiment #3: Metastatic burden in lungs of shScr injected mice vs shMet,failure,14.0,5.342071,Glass' delta,"[2.213625, 8.449566]",0.002276347,t,,13,0.2623192,Glass' delta,"[-0.8519444, 1.351713]",0.5567099,t,,https://doi.org/10.1038/nm.2753,Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa‐Silva; Gema Moreno‐Bueno; Marta Hergueta‐Redondo; Caitlin Williams; Guillermo García‐Santos; Cyrus M. Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A. Garcia; Margaret K. Callahan; Jianda Yuan; Vilma R. Martins; Johan Skog; Rosandra N. Kaplan; Mary S. Brady; Jedd D. Wolchok; Paul B. Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden,Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET,Nature Medicine,18,6.0,883,2012,https://doi.org/10.7554/eLife.39944
This study tested whether melanoma cells release exosomes that reprogram bone marrow cells to prepare distant sites for metastasis. Subexperiment #4: Metastatic burden in femurs of shScr injected mice vs liposome,failure,10.0,1.0,Cliff's delta,"[0.8490597, 1.0]",0.007936508,z,,12,0.05555556,Cliff's delta,"[-0.5361754, 0.6106755]",0.9372294,z,,https://doi.org/10.1038/nm.2753,Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa‐Silva; Gema Moreno‐Bueno; Marta Hergueta‐Redondo; Caitlin Williams; Guillermo García‐Santos; Cyrus M. Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A. Garcia; Margaret K. Callahan; Jianda Yuan; Vilma R. Martins; Johan Skog; Rosandra N. Kaplan; Mary S. Brady; Jedd D. Wolchok; Paul B. Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden,Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET,Nature Medicine,18,6.0,883,2012,https://doi.org/10.7554/eLife.39944
This study tested whether melanoma cells release exosomes that reprogram bone marrow cells to prepare distant sites for metastasis. Subexperiment #5: Metastatic burden in femurs of shScr injected mice vs shMet,failure,10.0,1.0,Cliff's delta,"[0.8490597, 1.0]",0.007936508,z,,13,9.27e-18,Cliff's delta,"[-0.5677269, 0.5677269]",1.0,z,,https://doi.org/10.1038/nm.2753,Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa‐Silva; Gema Moreno‐Bueno; Marta Hergueta‐Redondo; Caitlin Williams; Guillermo García‐Santos; Cyrus M. Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A. Garcia; Margaret K. Callahan; Jianda Yuan; Vilma R. Martins; Johan Skog; Rosandra N. Kaplan; Mary S. Brady; Jedd D. Wolchok; Paul B. Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden,Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET,Nature Medicine,18,6.0,883,2012,https://doi.org/10.7554/eLife.39944
This study tested whether PREX2 mutations found in melanoma promote tumor growth. Subexperiment #1: Tumor-free survival of GFP vs PREX2-G844D,success,20.0,4.079901,HR,"[1.067675, 15.590505]",0.03981128,z,,28,1.076923,HR,"[0.5062116, 2.2910642]",0.8474241,z,,https://doi.org/10.1038/nature11071,Michael F. Berger; Eran Hodis; Timothy P. Heffernan; Yonathan Lissanu Deribe; Michael S. Lawrence; Alexei Protopopov; Elena V. Ivanova; Ian R. Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert C. Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy R. Fennell; Scott L. Carter; Yotam Drier; Petar Stojanov; Meredith A. Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H. Ramos; Trevor J. Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer A. Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey Gabriel; Todd R. Golub; Stephan N. Wagner; Eric S. Lander; Gad Getz; Lynda Chin; Levi A. Garraway,Melanoma genome sequencing reveals frequent PREX2 mutations,Nature,485,7399.0,502,2012,https://doi.org/10.7554/eLife.21634
This study tested whether PREX2 mutations found in melanoma promote tumor growth. Subexperiment #2: Tumor-free survival of GFP vs PREX2-Q1430,failure,20.0,5.704528,HR,"[1.505061, 21.621469]",0.01042671,z,,22,0.968719,HR,"[0.4007011, 2.3419369]",0.9437466,z,,https://doi.org/10.1038/nature11071,Michael F. Berger; Eran Hodis; Timothy P. Heffernan; Yonathan Lissanu Deribe; Michael S. Lawrence; Alexei Protopopov; Elena V. Ivanova; Ian R. Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert C. Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy R. Fennell; Scott L. Carter; Yotam Drier; Petar Stojanov; Meredith A. Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H. Ramos; Trevor J. Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer A. Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey Gabriel; Todd R. Golub; Stephan N. Wagner; Eric S. Lander; Gad Getz; Lynda Chin; Levi A. Garraway,Melanoma genome sequencing reveals frequent PREX2 mutations,Nature,485,7399.0,502,2012,https://doi.org/10.7554/eLife.21634
This study tested whether PREX2 mutations found in melanoma promote tumor growth. Subexperiment #3: Tumor-free survival of PREX2-WT vs PREX2-G844D,failure,20.0,6.764221,HR,"[1.411818, 32.408353]",0.0167846,z,,21,0.808731,HR,"[0.3214712, 2.0345393]",0.6519858,z,,https://doi.org/10.1038/nature11071,Michael F. Berger; Eran Hodis; Timothy P. Heffernan; Yonathan Lissanu Deribe; Michael S. Lawrence; Alexei Protopopov; Elena V. Ivanova; Ian R. Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert C. Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy R. Fennell; Scott L. Carter; Yotam Drier; Petar Stojanov; Meredith A. Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H. Ramos; Trevor J. Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer A. Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey Gabriel; Todd R. Golub; Stephan N. Wagner; Eric S. Lander; Gad Getz; Lynda Chin; Levi A. Garraway,Melanoma genome sequencing reveals frequent PREX2 mutations,Nature,485,7399.0,502,2012,https://doi.org/10.7554/eLife.21634
This study tested whether PREX2 mutations found in melanoma promote tumor growth. Subexperiment #4: Tumor-free survival of PREX2-WT vs PREX2-Q1430,failure,20.0,9.370483,HR,"[1.96393, 44.70931]",0.005007683,z,,15,0.7121782,HR,"[0.2477023, 2.0476104]",0.5287432,z,,https://doi.org/10.1038/nature11071,Michael F. Berger; Eran Hodis; Timothy P. Heffernan; Yonathan Lissanu Deribe; Michael S. Lawrence; Alexei Protopopov; Elena V. Ivanova; Ian R. Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert C. Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy R. Fennell; Scott L. Carter; Yotam Drier; Petar Stojanov; Meredith A. Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H. Ramos; Trevor J. Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer A. Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey Gabriel; Todd R. Golub; Stephan N. Wagner; Eric S. Lander; Gad Getz; Lynda Chin; Levi A. Garraway,Melanoma genome sequencing reveals frequent PREX2 mutations,Nature,485,7399.0,502,2012,https://doi.org/10.7554/eLife.21634
This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #1: 2HG levels in cells expressing IDH1-WT vs IDH1-R132H,inconclusive,,,d,,,,,12,4.808061,d,"[2.419753, 7.14554]",6.23e-08,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #2: 2HG levels in cells expressing IDH2-WT vs IDH2-R132H,inconclusive,,,d,,,,,12,5.397198,d,"[2.785572, 7.962231]",9.71e-09,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #3: H3K4me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.8442984,r,"[0.5245781, 0.9553101]",0.01467993,F,,24,0.1300683,r,"[-0.2884638, 0.50687]",0.9470389,chi-squared,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #4: H3K9me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.8514205,r,"[0.5426985, 0.9574714]",0.0124397,F,,24,0.2678817,r,"[-0.1519333, 0.6058127]",0.6763842,F,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #5: H3K36me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",success,12.0,0.4364738,r,"[-0.1833576, 0.8079816]",0.6172321,F,,24,0.1893912,r,"[-0.2317079, 0.5507135]",0.8617649,F,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #6: H3K79me2 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.7277978,r,"[0.2642831, 0.9181871]",0.09492094,F,,24,0.2635354,r,"[-0.1564986, 0.6028442]",0.6715423,chi-squared,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #7: H3K9me2 levels in cells expressing IDH1-WT vs IDH1-R132H,failure,6.0,2.611829,d,"[0.1847137, 4.915465]",0.01263466,t,,12,0.1371508,d,"[-0.99936, 1.266919]",0.8146451,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #8: H3K9me2 levels in cells expressing IDH2-WT vs IDH2-R132H,success,6.0,3.454354,d,"[0.6033013, 6.205243]",0.002873608,t,,12,0.7591922,d,"[-0.4363171, 1.920202]",0.2034023,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #9: Correlation of 2HG levels and H3K4me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.744,r,"[0.2968469, 0.9235582]",0.005528176,t,,24,0.2322847,r,"[-0.1888034, 0.5812195]",0.2747297,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #10: Correlation of 2HG levels and H3K9me2 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.819,r,"[0.462472, 0.9475357]",0.001119253,t,,24,0.3104728,r,"[-0.1062284, 0.6344132]",0.139789,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #11: Correlation of 2HG levels and H3K9me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",success,12.0,0.732,r,"[0.2726285, 0.9195869]",0.006798659,t,,24,0.2762519,r,"[-0.1430907, 0.6115032]",0.191312,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #12: Correlation of 2HG levels and H3K36me3 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",success,12.0,0.667,r,"[0.150838, 0.8973882]",0.01782211,t,,24,0.1526915,r,"[-0.267161, 0.5238232]",0.476283,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #13: Correlation of 2HG levels and H3K79me2 levels in cells expressing IDH1-WT, IDH1-R132H, IDH2-WT, IDH2-R172K",failure,12.0,0.713,r,"[0.2354375, 0.9132196]",0.009242931,t,,24,0.1583788,r,"[-0.2617404, 0.5280394]",0.4598103,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
This study tested whether cancer-associated IDH mutations block cell differentiation by impairing histone demethylation. Subexperiment #14: 2HG levels in cells expressing IDH2-WT vs IDH2-R132H,inconclusive,,,d,,,,,10,9.062117,d,"[4.531949, 13.57112]",5.49e-07,t,,https://doi.org/10.1038/nature10860,Chao Lü; Patrick S. Ward; Gurpreet S. Kapoor; Dan Rohle; Şevin Turcan; Omar Abdel‐Wahab; Christopher R. Edwards; Raya Khanin; María E. Figueroa; Ari Melnick; Kathryn E. Wellen; Donald M. O’Rourke; Shelley L. Berger; Timothy A. Chan; Ross L. Levine; Ingo K. Mellinghoff; Craig B. Thompson,IDH mutation impairs histone demethylation and results in a block to cell differentiation,Nature,483,7390.0,474,2012,https://doi.org/10.7554/eLife.10860
"This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #1: Total RNA per 1000 cells at 0hr, 1hr, 24hr",failure,6.0,4.192694,d,"[0.9424328, 7.367756]",0.002146524,t,,6,0.8333723,d,"[-0.9053048, 2.483884]",0.3467888,t,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
"This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #2: Total RNA per 1000 cells at 0hr, 1hr, 24hr",success,6.0,4.192694,d,"[0.9424328, 7.367756]",0.002146524,t,,6,4.106256,d,"[0.9037742, 7.230549]",0.002382405,t,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #3: Active gene expression at 0 hr vs 1 hr,failure,755.0,0.5448031,r,"[0.4926005, 0.5930991]",1.05e-130,z,,708,0.3949782,r,"[0.3309264, 0.4554072]",1.36e-55,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #4: Active gene expression at 0 hr vs 1 hr,failure,755.0,0.5448031,r,"[0.4926005, 0.5930991]",1.05e-130,z,,719,0.3118873,r,"[0.2443428, 0.37642]",2.83e-34,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #5: Active gene expression at 0 hr vs 24 hr,failure,755.0,0.5985329,r,"[0.5507, 0.6424476]",3.33e-184,z,,708,0.2636816,r,"[0.1937634, 0.3309346]",3.6699999999999995e-24,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #6: Active gene expression at 0 hr vs 24 hr,failure,755.0,0.5985329,r,"[0.5507, 0.6424476]",3.33e-184,z,,719,0.3368036,r,"[0.2703445, 0.4000681]",3.77e-40,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #7: Active gene expression at 1 hr vs 24 hr,failure,755.0,0.5122673,r,"[0.4576434, 0.5630388]",6.09e-110,z,,708,0.1260148,r,"[0.05282251, 0.19786036]",1.92e-06,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #8: Active gene expression at 1 hr vs 24 hr,failure,755.0,0.5122673,r,"[0.4576434, 0.5630388]",6.09e-110,z,,719,0.2648761,r,"[0.1955467, 0.3315712]",9.91e-25,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #9: Silent gene expression at 0 hr vs 1 hr,reversal,514.0,-0.08532978,r,"[-0.20178932, 0.03350899]",0.04570119,z,,580,0.3702106,r,"[0.2977718, 0.4384106]",7.109999999999999e-40,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #10: Silent gene expression at 0 hr vs 1 hr,reversal,514.0,-0.08532978,r,"[-0.20178932, 0.03350899]",0.04570119,z,,573,0.2084408,r,"[0.1286578, 0.2855429]",9.29e-13,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #11: Silent gene expression at 0 hr vs 24 hr,success,514.0,0.1352899,r,"[0.0175003, 0.2493756]",0.001439705,z,,580,0.2447383,r,"[0.1665761, 0.319844]",2.22e-17,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #12: Silent gene expression at 0 hr vs 24 hr,success,514.0,0.1352899,r,"[0.0175003, 0.2493756]",0.001439705,z,,573,0.2411445,r,"[0.162373, 0.3168619]",1.03e-16,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #13: Silent gene expression at 1 hr vs 24 hr,failure,514.0,0.2672399,r,"[0.1444696, 0.3819071]",4.11e-09,z,,580,0.02012184,r,"[-0.06139251, 0.10136955]",0.4934609,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether cancer cells with high c-Myc levels show amplified transcription across the genome rather than activating specific target genes. Subexperiment #14: Silent gene expression at 1 hr vs 24 hr,failure,514.0,0.2672399,r,"[0.1444696, 0.3819071]",4.11e-09,z,,573,0.1310507,r,"[0.04967402, 0.21069895]",8.35e-06,z,,https://doi.org/10.1016/j.cell.2012.08.026,Charles Y. Lin; Jakob Lovén; Peter B. Rahl; Ronald M. Paranal; Christopher B. Burge; James E. Bradner; Tong Ihn Lee; Richard A. Young,Transcriptional Amplification in Tumor Cells with Elevated c-Myc,Cell,151,1.0,56,2012,https://doi.org/10.7554/eLife.30274
This study tested whether the bacterium Fusobacterium nucleatum is associated with colorectal cancer. Subexperiment #1: Change in F. nucleatum DNA in colorectal carcinoma vs adjacent normal tissue,failure,99.0,0.4507904,r,"[0.2781297, 0.5952318]",2.52e-06,t,,40,0.2389425,r,"[-0.07840262, 0.5123185]",0.03207874,z,,https://doi.org/10.1101/gr.126516.111,Mauro Castellarin; Robin M. Warren; Jamie Freeman; Lisa Dreolini; Martin Krzywinski; Jaclyn Strauss; Rebecca Barnes; Peter H. Watson; Emma Allen‐Vercoe; Richard A. Moore; Robert A. Holt,<i>Fusobacterium nucleatum</i> infection is prevalent in human colorectal carcinoma,Genome Research,22,2.0,299,2011,https://doi.org/10.7554/eLife.25801
